372 related articles for article (PubMed ID: 20950166)
1. Teriparatide and osseous regeneration in the oral cavity.
Bashutski JD; Eber RM; Kinney JS; Benavides E; Maitra S; Braun TM; Giannobile WV; McCauley LK
N Engl J Med; 2010 Dec; 363(25):2396-405. PubMed ID: 20950166
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide for bone loss in the jaw.
Grey A
N Engl J Med; 2010 Dec; 363(25):2458-9. PubMed ID: 20950165
[No Abstract] [Full Text] [Related]
3. Teriparatide and osseous regeneration in the jaw.
Finkelman RD; Reddy MS
N Engl J Med; 2011 Mar; 364(11):1080; author reply 1080-1. PubMed ID: 21410380
[No Abstract] [Full Text] [Related]
4. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.
Sim IW; Borromeo GL; Tsao C; Hardiman R; Hofman MS; Papatziamos Hjelle C; Siddique M; Cook GJR; Seymour JF; Ebeling PR
J Clin Oncol; 2020 Sep; 38(26):2971-2980. PubMed ID: 32614699
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw.
Cheung A; Seeman E
N Engl J Med; 2010 Dec; 363(25):2473-4. PubMed ID: 20950167
[No Abstract] [Full Text] [Related]
6. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.
Bhandari M; Jin L; See K; Burge R; Gilchrist N; Witvrouw R; Krohn KD; Warner MR; Ahmad QI; Mitlak B
Clin Orthop Relat Res; 2016 May; 474(5):1234-44. PubMed ID: 26932738
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
8. The impact of vitamin D status on periodontal surgery outcomes.
Bashutski JD; Eber RM; Kinney JS; Benavides E; Maitra S; Braun TM; Giannobile WV; McCauley LK
J Dent Res; 2011 Aug; 90(8):1007-12. PubMed ID: 21555774
[TBL] [Abstract][Full Text] [Related]
9. More on the resolution of bisphosphonate-associated osteonecrosis of the jaw.
Tsai KY; Huang CS; Huang GM; Yu CT
J Rheumatol; 2010 Mar; 37(3):675; author reply 676. PubMed ID: 20197569
[No Abstract] [Full Text] [Related]
10. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Keel C; Kraenzlin ME; Kraenzlin CA; Müller B; Meier C
J Bone Miner Metab; 2010; 28(1):68-76. PubMed ID: 19633810
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide therapy for osteonecrosis of the jaw.
Chtioui H; Lamine F; Daghfous R
N Engl J Med; 2011 Mar; 364(11):1081-2; author reply 1082. PubMed ID: 21410382
[No Abstract] [Full Text] [Related]
12. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
13. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw.
Cha YH; Hong N; Rhee Y; Cha IH
Osteoporos Int; 2018 Apr; 29(4):987-992. PubMed ID: 29249017
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S
Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957
[TBL] [Abstract][Full Text] [Related]
17. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
[TBL] [Abstract][Full Text] [Related]
18. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
19. Systemic Teriparatide Administration Promotes Osseous Regeneration of an Intrabony Defect: A Case Report.
Bashutski JD; Kinney JS; Benavides E; Maitra S; Braun TM; Giannobile WV; McCauley LK; Eber RM
Clin Adv Periodontics; 2012 May; 2(2):66-71. PubMed ID: 26525954
[TBL] [Abstract][Full Text] [Related]
20. Anabolic therapy for osteoporosis.
Bilezikian JP
Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
